OncoMatch/Clinical Trials/NCT06819007
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Is NCT06819007 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Trastuzumab Deruxtecan and Bevacizumab for ovarian cancer.
Treatment: Trastuzumab Deruxtecan · Bevacizumab — This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Ovarian Cancer
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 3+/2+/1+ (ASCO-CAP gastric cancer IHC scoring 2016))
HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+/2+/1+) guidelines by prospective central testing
Excluded: BRCA1 deleterious alteration
Has a known or suspected deleterious BRCA alteration as per local test that makes the patient eligible for PARP inhibitor
Excluded: BRCA2 deleterious alteration
Has a known or suspected deleterious BRCA alteration as per local test that makes the patient eligible for PARP inhibitor
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
Grade: high-grade
newly diagnosed FIGO Stage III or IV
Demographics
Prior therapy
Must have received: bevacizumab in combination with frontline platinum-based chemotherapy (bevacizumab, platinum-based chemotherapy) — frontline
Has received up to 6 cycles of standard of care bevacizumab in combination with frontline platinum-based chemotherapy as per approved indication and clinical guidelines and is eligible to continue single agent bevacizumab maintenance
Cannot have received: PARP inhibitor
Participant to receive PARP inhibitor as maintenance per standard of care and investigator discretion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Scripps Clinic · La Jolla, California
- Broward Health Medical Center · Fort Lauderdale, Florida
- Jupiter Medical Center · Jupiter, Florida
- Mount Sinai Medical Center · Miami Beach, Florida
- AdventHealth Cancer Institute · Orlando, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06819007 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 deleterious alteration is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 deleterious alteration is an exclusion criterion.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify